Skip to main content

Immunovant, Inc.

IMVT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001764013

In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Immunovant, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
10 filings
6 insiders, $1.12M in total
Insiders trading
6
Net value
−$1.12M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Immunovant, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Immunovant, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Van Tuyl ChristopherChief Legal Officer176,545Sep 25, 20268
Pande AtulDirector116,731Aug 28, 20266
Gloria MelanieChief Operating Officer219,301Aug 21, 20268
Girao TiagoChief Financial Officer240,798Jul 24, 20264
Stout Jay SChief Technology Officer205,341Jul 24, 202610
Venker EricChief Executive Officer254,280Jul 6, 20263
Fromkin Andrew J.Director74,382May 29, 20263
Susman Robert GrahamDirector36,394May 1, 20262
Torti FrankDirector1,009,228Apr 9, 20261
Bauer JakeDirector38,896Apr 9, 20261
Hughes Douglas J.Director134,653Apr 9, 20262
Roivant Sciences Ltd.Director, 10% Owner113,317,007Dec 12, 20251
Geffner MichaelChief Medical Officer217,958Oct 24, 20252
Salzmann PeterChief Executive Officer1,178,191Apr 17, 20250
Barnett Eva ReneeChief Financial Officer396,774Apr 17, 20250
Migausky George VDirector137,251Apr 3, 20250
Macias William L.Chief Medical Officer357,353Feb 21, 20250
Levine Mark S.Chief Legal Officer319,228Nov 22, 20240
Butchko Julia G.Chief Development Officer440,959Aug 23, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 11, 2021 (view filing)Aug 101 dayFromkin Andrew J.DirectorPPurchase+5.50K$7.90+$43.5K+13.7%45.7K after
Aug 16, 2021 (view filing)Aug 133 daysPande AtulDirectorPPurchase+5.00K$7.98+$39.9K+12.4%45.2K after
Aug 20, 2021 (view filing)Aug 20Same dayMigausky George VDirectorPPurchase+7.00K$7.65+$53.5K+11.6%67.2K after
Aug 30, 2021 (view filing)Aug 273 daysHughes Douglas J.DirectorPPurchase+18.2K$8.24+$150.4K+45.4%58.4K after
Jan 7, 2022 (view filing)Jan 52 daysMacias William L.Chief Medical OfficerSSale−26.8K$8.28−$222.0K−12.0%197.3K after
Jan 11, 2022 (view filing)Jan 74 daysSalzmann PeterChief Executive OfficerSSale−125.2K$7.25−$907.4K−17.8%578.0K after
Jan 11, 2022 (view filing)Jan 74 daysBarnett Eva ReneeChief Financial OfficerSSale−30.0K$7.25−$217.2K−14.8%172.5K after
Jan 11, 2022 (view filing)Jan 74 daysButchko Julia G.Chief Dev. & Tech. OfficerSSale−55.3K$7.25−$401.1K−16.0%289.5K after
Apr 14, 2022 (view filing)Mar 2421 daysLateSalzmann PeterChief Executive OfficerSSale−19.2K$5.90−$113.4K−3.3%558.7K after
Apr 14, 2022 (view filing)Mar 2421 daysLateButchko Julia G.Chief Dev. & Tech. OfficerSSale−6.38K$5.90−$37.6K−2.2%283.1K after
Apr 20, 2022 (view filing)Apr 191 dayMacias William L.Chief Medical OfficerSSale−1.39K$4.98−$6.93K−0.7%195.9K after
Apr 29, 2022 (view filing)Apr 272 daysSalzmann PeterChief Executive OfficerSSale−1.62K$4.72−$7.66K−0.3%557.1K after
Apr 29, 2022 (view filing)Apr 272 daysButchko Julia G.Chief Dev. & Tech. OfficerSSale−541$4.72−$2.55K−0.2%282.6K after
May 25, 2022 (view filing)May 241 daySalzmann PeterChief Executive OfficerSSale−1.47K$3.79−$5.58K−0.3%555.6K after
May 25, 2022 (view filing)May 241 dayButchko Julia G.Chief Dev. & Tech. OfficerSSale−492$3.79−$1.86K−0.2%282.1K after
Jul 1, 2022 (view filing)Jun 292 daysButchko Julia G.Chief Dev. & Tech. OfficerSSale−460$4.02−$1.85K−0.2%281.6K after
Jul 1, 2022 (view filing)Jun 292 daysSalzmann PeterChief Executive OfficerSSale−1.38K$4.02−$5.53K−0.2%554.3K after
Jul 26, 2022 (view filing)Jul 224 daysMacias William L.Chief Medical OfficerSSale−322$4.70−$1.51K−0.2%195.6K after
Jul 29, 2022 (view filing)Jul 272 daysSalzmann PeterChief Executive OfficerSSale−1.53K$4.27−$6.52K−0.3%552.7K after
Jul 29, 2022 (view filing)Jul 272 daysButchko Julia G.Chief Dev. & Tech. OfficerSSale−510$4.27−$2.18K−0.2%281.1K after
Sep 1, 2022 (view filing)Aug 302 daysButchko Julia G.Chief Dev. & Tech. OfficerSSale−548$5.83−$3.19K−0.1%393.4K after
Sep 1, 2022 (view filing)Aug 302 daysSalzmann PeterChief Executive OfficerSSale−1.64K$5.83−$9.58K−0.2%1.00M after
Sep 29, 2022 (view filing)Sep 29Same dayTorti FrankDirectorPPurchase+20.0K$5.81+$116.2K+5.4%393.4K after
Sep 29, 2022 (view filing)Sep 281 daySalzmann PeterChief Executive OfficerSSale−1.60K$4.67−$7.50K−0.2%1.00M after
Sep 29, 2022 (view filing)Sep 281 dayButchko Julia G.Chief Dev. & Tech. OfficerSSale−535$4.67−$2.50K−0.1%392.8K after
Oct 4, 2022 (view filing)Sep 304 daysPande AtulDirectorPPurchase+15.0K$5.60+$84.0K+300.0%20.0K after
Oct 7, 2022 (view filing)Oct 61 dayRoivant Sciences Ltd.10% OwnerPPurchaseCommon Stock, $0.0001 par value per share+416.7K$6.00+$2.50M+0.6%73.8M after
Oct 13, 2022 (view filing)Oct 112 daysBarnett Eva ReneeChief Financial OfficerSSale−12.5K$9.44−$118.0K−4.4%272.9K after
Oct 17, 2022 (view filing)Oct 134 daysSalzmann PeterChief Executive OfficerSSale−2.79K$9.18−$25.6K−0.3%998.0K after
Oct 17, 2022 (view filing)Oct 134 daysButchko Julia G.Chief Dev. & Tech. OfficerSSale−928$9.18−$8.52K−0.2%391.9K after
Oct 25, 2022 (view filing)Oct 214 daysMacias William L.Chief Medical OfficerSSale−341$9.67−$3.30K−0.1%308.1K after
Jan 13, 2023 (view filing)Jan 112 daysMacias William L.Chief Medical OfficerSSale−44.6K$16.75−$746.3K−14.5%263.5K after2 lots
Jan 13, 2023 (view filing)Jan 112 daysBarnett Eva ReneeChief Financial OfficerSSale−4.51K$16.75−$75.5K−1.7%268.3K after2 lots
Jan 13, 2023 (view filing)Jan 112 daysButchko Julia G.Chief Dev. & Tech. OfficerSSale−60.5K$16.79−$1.02M−15.4%331.4K after2 lots
Jan 13, 2023 (view filing)Jan 112 daysSalzmann PeterChief Executive OfficerSSale−4.02K$16.80−$67.6K−0.4%993.9K after
Jan 27, 2023 (view filing)Jan 261 dayLevine Mark S.Chief Legal OfficerSSale−10.2K$18.51−$188.0K−4.0%245.7K after
Feb 3, 2023 (view filing)Feb 21 dayMacias William L.Chief Medical OfficerSSale−537$18.24−$9.79K−0.2%263.0K after
Apr 19, 2023 (view filing)Apr 181 daySalzmann PeterChief Executive OfficerSSale−3.40K$15.27−$51.8K−0.3%1.23M after
Apr 19, 2023 (view filing)Apr 181 dayButchko Julia G.Chief Development OfficerSSale−1.54K$15.27−$23.6K−0.4%430.1K after
Apr 19, 2023 (view filing)Apr 181 dayBarnett Eva ReneeChief Financial OfficerSSale−3.42K$15.27−$52.3K−1.0%352.6K after
Apr 26, 2023 (view filing)Apr 251 dayLevine Mark S.Chief Legal OfficerSSale−2.63K$16.29−$42.9K−0.8%330.7K after
Apr 26, 2023 (view filing)Apr 251 dayMacias William L.Chief Medical OfficerSSale−509$16.29−$8.29K−0.1%350.2K after
Jul 13, 2023 (view filing)Jul 121 dayButchko Julia G.Chief Development OfficerSSale−1.47K$19.73−$29.0K−0.3%428.6K after
Jul 13, 2023 (view filing)Jul 121 daySalzmann PeterChief Executive OfficerSSale−3.23K$19.73−$63.8K−0.3%1.23M after
Jul 20, 2023 (view filing)Jul 191 dayBarnett Eva ReneeChief Financial OfficerSSale−2.73K$24.94−$68.0K−0.8%349.9K after
Jul 20, 2023 (view filing)Jul 191 dayMacias William L.Chief Medical OfficerSSale−426$24.94−$10.6K−0.1%349.7K after
Jul 27, 2023 (view filing)Jul 261 dayLevine Mark S.Chief Legal OfficerSSale−3.92K$21.63−$84.7K−1.2%326.8K after
Aug 8, 2023 (view filing)Aug 71 daySalzmann PeterChief Executive OfficerSSale−101.3K$21.73−$2.20M−8.2%1.13M after
Aug 16, 2023 (view filing)Aug 142 daysSalzmann PeterChief Executive OfficerSSale−103.1K$21.42−$2.21M−9.1%1.03M after2 lots
Aug 25, 2023 (view filing)Aug 241 dayMacias William L.Chief Medical OfficerSSale−12.3K$20.30−$250.4K−3.5%337.4K after2 lots